Related Experiment Videos
Plasmapheresis in glomerulonephritis
Insights
Plasmapheresis combined with immunosuppressive drugs safely and effectively treated 17 glomerulonephritis patients. This procedure reduced key inflammatory markers, improving kidney function and patient well-being.
Area of Science:
- Nephrology
- Immunology
Background:
- Glomerulonephritis encompasses various kidney diseases characterized by inflammation of the glomeruli.
- Treatment often involves immunosuppressive drugs, but efficacy can be limited in certain conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of plasmapheresis combined with immunosuppressive therapy in diverse glomerulonephritis cases.
- To assess the impact of plasmapheresis on specific immunological markers and renal function.
Main Methods:
- Seventeen patients with various forms of glomerulonephritis received plasmapheresis using a Haemonetics Model 30 device.
- Two liters of plasma were exchanged with a solution of 5% albumin in Hartmann's solution.
- Patients also underwent immunosuppressive drug therapy.
Main Results:
- Plasmapheresis was found to be a safe and effective procedure, albeit relatively expensive.
- Significant reductions were observed in fibrinogen, complement components, anti-glomerular basement membrane antibody, and immune complex levels.
- Improvement in renal function and clinical well-being was noted in patients, particularly those with Goodpasture's syndrome and lupus erythematosus.
Conclusions:
- Plasmapheresis, alongside immunosuppressive drugs, offers a viable treatment option for specific glomerulonephritis subtypes.
- The reduction of circulating immune factors is a likely mechanism contributing to therapeutic benefits.
- Further research may explore cost-effectiveness and long-term outcomes.
Abstract:
Plasmapheresis together with immunosuppressive drug therapy has been used in the treatment of 17 patients with glomerulonephritis [Goodpasture's syndrome (4), systemic lupus erythematosus (4), mesangiocapillary glomerulonephritis (2), glomerulonephritis associated with cirrhosis (2), nonspecific mesangial proliferative glomerulonephritis (3), Henoch-Schoenlein purpura glomerulonephritis (1) and glomerulonephritis associated with infective endocarditis (1)]. Use of the Haemonetics Model 30 blood cell separator, exchanging two liters of plasma with 5% albumin in Hartmann's solution has provided a safe, effective but relatively expensive procedure, capable of producing a marked reduction of fibrinogen, complement components, anti-glomerular basement membrane antibody and immune complex concentrations. Removal of one or more of these factors is felt to be at least partly responsible for the improvement in renal function and clinical well-being demonstrated in patients with Goodpasture's syndrome, systemic lupus erythematosus and other forms of glomerulonephritis associated with the presence of circulating immune complexes.